Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:QNRX 11 October 2025 - 11 November 2025

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals announced it achieved 4% rapamycin in a topical lotion and 5% in a dermal patch, clearing a key formulation barrier for human trials. QNRX shares surged, with pre-market gains near 66%. Clinical and stability batch manufacturing is set for late 2025, with first-in-human studies planned for early 2026 targeting microcystic lymphatic and venous malformations.
11 November 2025
···
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharmaceuticals shares surged over 150% on Oct. 10, closing at $20.50 after announcing a $104.5 million private placement with institutional healthcare investors. Intraday, the stock touched $41.80 before retreating. Market cap rose to about $160–170 million. The company, which has no products on the market, is developing QRX003 for Netherton Syndrome and recently secured FDA and EMA orphan drug designations.
11 October 2025
·
Go toTop